TY - JOUR
T1 - Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers
T2 - ASCO Guideline
AU - Yilmaz, Emrullah
AU - Ismaila, Nofisat
AU - Bauman, Julie E.
AU - Dabney, Raetasha
AU - Gan, Gregory
AU - Jordan, Richard
AU - Kaufman, Marnie
AU - Kirtane, Kedar
AU - McBride, Sean Matthew
AU - Old, Matthew O.
AU - Rooper, Lisa
AU - Saba, Nabil F.
AU - Sheth, Siddharth
AU - Subramaniam, Rathan M.
AU - Wise-Draper, Trisha Michel
AU - Wong, Deborah
AU - Mell, Loren K.
N1 - Publisher Copyright: © American Society of Clinical Oncology.
PY - 2023/2/10
Y1 - 2023/2/10
N2 - PURPOSETo provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers.METHODSASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-Analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 28 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSWhen possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
AB - PURPOSETo provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers.METHODSASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-Analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 28 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSWhen possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85147720716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147720716&partnerID=8YFLogxK
U2 - 10.1200/JCO.22.02328
DO - 10.1200/JCO.22.02328
M3 - Article
C2 - 36521102
SN - 0732-183X
VL - 41
SP - 1132
EP - 1146
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 5
ER -